<DOC>
	<DOC>NCT01086280</DOC>
	<brief_summary>The purpose of this study is to compare the incidence of major cardiovascular events among patients with type 2 diabetes who are new initiators of Saxagliptin and those who are new initiators of oral anti-diabetic drugs (OADs)in classes other than Dipeptidyl peptidase IV (DPP4) inhibitors.</brief_summary>
	<brief_title>Risk of Cardiovascular Events in Patients With Type 2 Diabetes Initiating Oral Antidiabetic Treatments</brief_title>
	<detailed_description>Prospectively designed retrospective database study. This study will be conducted using administrative claims data and electronic medical records that are collected as part of routine clinical practice</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Saxagliptin</mesh_term>
	<mesh_term>Hypoglycemic Agents</mesh_term>
	<criteria>18 years of age or older Newly prescribed Saxagliptin or an OAD in a class other than DPP4 inhibitors Enrolled in the respective database for at least 180 days prior to the first prescription for Saxagliptin or other OAD in a class other than DPP4 inhibitors Patients identified with a diagnostic code for any of the cardiovascular outcomes of interest within the 180day baseline period Patients prescribed a DPP4 inhibitor during the baseline period</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>